SCA
PDSB icon

Sassicaia Capital Advisers’s PDS Biotechnology PDSB Stock Holding History

Sassicaia Capital Advisers’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-14,000
Closed -$185K – 45
2022
Q4 		$185K Buy
+14,000
New +$98.8K 0.46% 25
2022
Q1 		– Sell
-75,200
Closed -$609K – 30
2021
Q4 		$609K Buy
+75,200
New +$809K 4.2% 7

Other funds holding PDSB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
EWA
EP Wealth Advisors Torrance, California $20.3B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sassicaia Capital Advisers's PDSB Position: Q1 2023 in Review

Sassicaia Capital Advisers sold out of PDS Biotechnology (PDSB) in Q1 2023, closing a stake of 14,000 shares — an estimated $185K sold.

Sassicaia Capital Advisers first reported a position in PDSB in Q4 2021 and held it in 2 quarters. The position peaked at $609K in Q4 2021. 68 funds tracked by Wall St. Rank hold PDSB as of Q1 2023.

  • Sassicaia Capital Advisers reported no remaining PDS Biotechnology position as of Q1 2023 after selling out during the quarter.
  • Sassicaia Capital Advisers sold 14,000 PDS Biotechnology shares in Q1 2023, an estimated $185K.
  • Sassicaia Capital Advisers first reported a position in PDS Biotechnology in Q4 2021 and held it in 2 quarters.
  • Sassicaia Capital Advisers's PDS Biotechnology position peaked at $609K in Q4 2021.
  • 68 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2023.

Based on Sassicaia Capital Advisers's 13F filing for Q1 2023, filed 15 May 2023.